The present disclosure relates to methods for preventing, ameliorating or treating complications caused by a viral infection (e.g., SARS, SARS-cov2, MERS, Influenza etc.), by administration of an immune response modulating agent (IRMA).

The present disclosure relates to methods for preventing, ameliorating or treating complications caused by a viral infection (e.g., SARS, SARS-cov2, MERS, Influenza etc.), by administration of an immune response modulating agent (IRMA).

The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C.sub.3-C.sub.8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C.sub.3-C.sub.8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C.sub.3-C.sub.8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.

Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.

Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.

Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.